2. Search Result
Search Result
Isoforms Recommended: NMDA Receptor
Results for "

GluN2A

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13457
    TCN 201
    1 Publications Verification

    		 iGluR Neurological Disease
    TCN 201 is a potent, selective and non-competitive antagonist of GluN1/GluN2A NMDA receptor, with a pIC50 of 6.8. TCN 201 is selective for GluN1/GluN2A NMDA receptor over GluN1/GluN2B NMDA receptor (pIC50<4.3) [2].
    TCN 201
  • HY-107498
    GNE-8324

    		iGluR Neurological Disease
    GNE-8324 is a selective GluN2A positive allosteric modulator. GNE-8324 selectively enhances NMDA receptor (NMDAR)-mediated synaptic responses in inhibitory but not excitatory neurons .
    GNE-8324
  • HY-107409
    GNE 5729

    		iGluR Neurological Disease
    GNE 5729 is a brain permeable positive allosteric modulator of NMDAR, with an EC50 of 37 nM for GluN2A, 4.7 and 9.5 μM for GluN2C and GluN2D, respectively.
    GNE 5729
  • HY-107423
    GNE 6901

    		iGluR Neurological Disease
    GNE 6901 (compound 40) is a potent GluN2A-selective NMDAR positive allosteric modulator (PAM) with an EC50 of 382 nM .
    GNE 6901
  • HY-148939
    MPX-004

    		iGluR Neurological Disease
    MPX-004 is a potent GluN2A antagonist. MPX-004 inhibits GluN2A-containing NMDA receptors expressed in HEK cells with an IC50 of 79 nM. MPX-004 has no inhibitory effect on GluN2B or GluN2D receptor-mediated responses. MPX-004 has the potential for neuropsychiatric and developmental disorders research .
    MPX-004
  • HY-116483
    MPX-007

    		iGluR Neurological Disease
    MPX-007 is a GluN2A antagonist (IC50: 27 nM). MPX-007 is a tools to probe GluN2A physiology, and to study neuropsychiatric and developmental disorders .
    MPX-007
  • HY-100839
    (RS)-(Tetrazol-5-yl)glycine

    D,L-(tetrazol-5-yl)glycine; LY 285265

    		 iGluR Neurological Disease
    (RS)-(Tetrazol-5-yl)glycine (D,L-(tetrazol-5-yl)glycine) is a highly potent and selective N-methyl-D-aspartate (NMDA) receptor agonist . (RS)-(Tetrazol-5-yl)glycine has EC50s of 99 nM, 1.7 μM for GluN1/GluN2D and GluN1/GluN2A, respectively [2]. (RS)-(Tetrazol-5-yl)glycine induces seizure responses and Fos in mice .
    (RS)-(Tetrazol-5-yl)glycine
  • HY-124264
    UBP710

    		iGluR Neurological Disease
    UBP710 is a selective NMDA receptor modulator. UBP710 displays greater activity in potentiating GluN2B-containing receptors than those containing GluN2A .
    UBP710
  • HY-108337
    GNE-0723

    		iGluR Neurological Disease
    GNE-0723 is a brain permeable positive allosteric modulator of NMDAR, with an EC50 of 21 nM for GluN2A, 7.4 and 6.2 μM for GluN2C and GluN2D, respectively .
    GNE-0723
  • HY-120074
    UBP512

    		Others Others
    UBP512 is an NMDA receptor modulator with the activity to regulate NMDA receptor activity. UBP512 is a GluN2A-selective enhancer and GluN2C and GluN2D inhibitor, belonging to a new generation of NMDA receptor modulators, which may have potential effects on the study and inhibition of related neurological diseases.
    UBP512
  • HY-107712
    TCN 213

    		iGluR Neurological Disease
    TCN 213 is a selective, surmountable, glycine-dependentlly GluN1/GluN2A NMDAR antagonist with IC50s of 0.55, 3.5, 40 μM in the presence of 75, 750, 7500 nM glycine, respectively. TCN 213 can be used to monitor, pharmacologically, the switch in NMDAR expression in developing cortical neurones [2].
    TCN 213
  • HY-148250
    TP-050

    		iGluR Neurological Disease
    TP-050 is a potent, orally active and selective NMDAR agonist with an EC50 value of 0.51 µM and 9.6 µM for GluN2A and GluN2D, respecticely. TP-050 can cross the blood-brain barrier (BBB). TP-050 induces hippocampal long-term (LPT) potentiation enhancemen and enhances neuronal signal transmission .
    TP-050
  • HY-120523
    UBP646

    		iGluR Neurological Disease
    UBP646 is a potent GluN1/GluN2D receptors potentiator, and also potentiates the other three subtypes, GluN1/GluN2A, GluN1/GluN2B, and GluN1/GluN2C receptors .
    UBP646
  • HY-135741
    NYX-2925

    		iGluR Neurological Disease
    NYX-2925 is an orally active NMDAR modulator. NYX-2925 restores levels of activated Src and Src phosphorylation sites on GluN2A and GluN2B in the mPFC. NYX-2925 shows no effect on CAMKII, and any addictive or sedative/ataxic side effects. NYX-2925 can be used for research of a variety of NMDA receptor-mediated central nervous system disorders [2].
    NYX-2925
  • HY-107711
    DQP-1105

    		iGluR Neurological Disease
    DQP-1105 is a potent noncompetitive NMDA receptor antagonist. DQP-1105 inhibits GluN2C- and GluN2D-containing receptors (IC50=7.0 and 2.7 μM, respectively). The IC50 values are at least 50-fold lower than those for recombinant GluN2A-, GluN2B-, GluA1-, or GluK2-containing receptors .
    DQP-1105
  • HY-124569
    NAB-14

    		iGluR Neurological Disease
    NAB-14 is a potent, selective, orally active and non-competitive GluN2C/2D antagonists with an IC50 of 580 nM for GluN1/GluN2D. NAB-14 shows >800-fold selective for recombinant GluN2C and GluN2D over GluN2A and GluN2B. NAB-14 can cross the blood-brain-barrier .
    NAB-14
  • HY-117734
    PYD-106

    		iGluR Neurological Disease
    PYD-106 is a stereoselective pyrrolidinone (PYD) positive allosteric modulator for GluN2C-containing NMDA receptors. PYD-106 increases opening frequency and open time of single channel currents activated by maximally effective concentrations of agonist but only has modest effects on glutamate and glycine EC50. PYD-106 selectively enhances the responses of diheteromeric GluN1/GluN2C receptors but not triheteromeric GluN1/GluN2A/GluN2C receptors .
    PYD-106

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: